Pharmaceuticals company Hester Biosciences announced Q2FY26 results Revenue from operations: Rs 709.69 million against Rs 836.92 million during Q2FY25, change -15%. EBITDA: Rs 235.97 million against Rs 219.55 million during Q2FY25, change 7%. EBITDA Margin: 33% for Q2FY26. PAT: Rs 143.31 million against Rs 83.91 million during Q2FY25, change 71%. PAT Margin: 20% for Q2FY26. EPS: Rs 16.85 for Q2FY26. Result PDF